GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting
These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.
- These results were presented at the 64th American Society of Hematology (ASH) Annual Meeting.
- The studies describe safety and preliminary efficacy in frontline unfit and treated secondary AML populations not previously studied with this novel investigational agent, said Edwin Rock, M.D., Ph.D., Chief Medical Officer.
- These presentations provide the first uproleselan clinical data in AML generated outside of company-sponsored studies.
- A majority of 15 patients enrolled were male (n=10) with ECOG status of less than 2 (ECOG 0=1; 1=10; 2=4).